Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (131-140 of 162) with videos related to

Pageof 17
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Lancet (London, England)|April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialHarry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncologyPeter L Greenberg, Maria R Baer, John M Bennett, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2026
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Giovanni Marconi, Pau Montesinos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Myeloid growth factorsJeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Myelodysplastic syndromesPeter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Myeloid growth factors. Clinical practice guidelines in oncologyJeffrey Crawford, Betsy Althaus, James Armitage, et al.
Pageof 17

Showing results (131-140 of 162) with videos related to

Sort By:
Pageof 17
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2015
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaRichard M Stone, Emanuele Mazzola, Donna Neuberg, et al.
Lancet (London, England)|April 28, 2023
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trialHarry P Erba, Pau Montesinos, Hee-Je Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 13, 2006
Myelodysplastic syndromes clinical practice guidelines in oncologyPeter L Greenberg, Maria R Baer, John M Bennett, et al.
Medrxiv : the Preprint Server for Health Sciences|November 24, 2025
Prognostic impact of age and MDS-associated mutations in <i>NPM1</i> -mutated AMLVivian M Liu, Megan Othus, Jasmine Naru, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2017
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117Mikkael A Sekeres, Megan Othus, Alan F List, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2026
Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell NeoplasmNaveen Pemmaraju, Giovanni Marconi, Pau Montesinos, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 30, 2009
Myeloid growth factorsJeffrey Crawford, James Armitage, Lodovico Balducci, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 18, 2008
Myelodysplastic syndromesPeter L Greenberg, Eyal Attar, Minoo Battiwalla, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 6, 2007
Myeloid growth factors. Clinical practice guidelines in oncologyJeffrey Crawford, Betsy Althaus, James Armitage, et al.
Pageof 17